Last reviewed · How we verify

prostate cancer with suspected metastasis — Treatment Landscape & Competitive Intelligence

prostate cancer with suspected metastasis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating prostate cancer with suspected metastasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Posluma FLOTUFOLASTAT Blue Earth Radioactive Diagnostic Agent [EPC] 2025-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Blue Earth · 1 drug in prostate cancer with suspected metastasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in prostate cancer with suspected metastasis:

Cite this brief

Drug Landscape (2026). prostate cancer with suspected metastasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/prostate-cancer-with-suspected-metastasis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing